# Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

> **NCT03659435** · PHASE1 · COMPLETED · sponsor: **SocraTec R&D GmbH** · enrollment: 58 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** RID-TDS 9.5 mg/24 h
- **DRUG:** Exelon® 9.5 mg/24 h

## Key facts

- **NCT ID:** NCT03659435
- **Lead sponsor:** SocraTec R&D GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-22
- **Primary completion:** 2018-11-28
- **Final completion:** 2018-11-28
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2019-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03659435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03659435, "Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03659435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*